close

Enter

Log in using OpenID

Back Pain Therapy Market Value Projected to Expand by 2018-2026

embed
Back pain is mainly caused due to muscular strains, strained ligaments, and muscular spasms in any region of the back. Chronic diseases such as herniated discs, arthritis, and osteoporosis can lead to back pain. Depending on the severity of the symp
Back Pain Therapy Market Value Projected to
Expand by 2018-2026
Back Pain Therapy Market, By Drug Type (Non-steroidal Anti-Inflammatory
Drugs, Analgesics, Muscle Relaxants, and Others), By Indication (Herniated
Disc, Arthritis, Osteoporosis, and Others), By Distribution Channel (Hospital
Pharmacies, Online Pharmacies, and Retail Pharmacies), and By Geography Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2018-2026
Back pain is mainly caused due to muscular strains, strained ligaments, and muscular spasms in any
region of the back. Chronic diseases such as herniated discs, arthritis, and osteoporosis can lead to back
pain. Depending on the severity of the symptoms, back pain can be categorized- into acute and chronic
back pain. Acute pain is most common type of back pain, which can be treated by medication. Click To
Read More On Back Pain Therapy Market.
Increasing prevalence of back pain among geriatric population is expected to boost growth of the
global back pain therapy market
According to study published by Centre for Disea0se Control and Prevention (CDC) in 2012, around
20.3% of population was suffering from lower back pain in U.S. Moreover, according to study
published by American Chronic Association in 2010, around 80% of population is projected to
experience back pain once in a life. Therefore, increasing prevalence of back pain is expected to propel
demand for back pain treatment, which in turn is expected to drive growth of global back pain therapy
market over the forecast period. Furthermore, increasing ageing population is also expected to drive
growth of the market, as chances of back pain increases with the age. According to study published by
National Centre for Biotechnology Information (NCBI) in 2015, around 19.6% of individuals aged
between 20 to 60 years were suffering from low back pain worldwide. According to the United Nations
Economic and Social Commission for Asia and the Pacific (ESCAP) 2016, around 547 million people
were above 60 years in Asia Pacific region and number is projected to reach around 1.3 billion by 2050.
Increasing geriatric population in key regions such as North America, Europe, and Asia Pacific is
expected to drive growth of the global back pain therapy market.
Ask For Sample Copy Of This Business Research Report :
https://www.coherentmarketinsights.com/insight/request-sample/1374
Key Companies
Key players operating in back pain therapy market include Celebrex, H.J. Harkins Company, Inc.,
Pfizer, Inc., Cipla Ltd., Apotex Inc., Jubilant Generics Ltd, Purdue Pharma L.P., Johnson & Johnson,
Lupin Ltd., and Teva Pharmaceutical Industries Ltd.
North America is expected to hold a dominant position in global back pain therapy market,
owing to development of new therapies
In 2017, U.S.-based Pfizer Inc. and Eli Lilly and company received the U.S. Food and Drug
Administration (FDA) fast track designation for its drug tanezumab, which is indicated for the
treatment of chronic low back pain. Tanezumab is a humanized monoclonal immunoglobulin G2
(IgG2), which could be used as an alternative to opioids. The development of such novel drugs in the
U.S. is expected to drive growth of the market in North America. Asia Pacific is expected to be the
second largest market for global back pain therapy market due to increasing prevalence of back pain in
ageing population. According to a study published by United Nations Economic and Social
Commission for Asia and the Pacific (ESCAP) in 2016, Asia Pacific region constitutes around 60% of
the world’s geriatric population. According to study published by World Health Organization (WHO) in
2016, an estimated one out of six people in India are projected to suffer from arthritis once in life.
Also, Coherent Market Insights has a proprietary database of pipeline biologics and biosimilars, called
PHASE-XS. This database provides analytical data in addition to the clinical information of ongoing
trials for biologics and biosimilars. An amalgamation of more than 30 parameters, PHASE-XS helps
biotechnology and pharmaceutical companies to analyze the market trend, competition, and market
potential. For more information or to access this database, kindly click on the below link or contact at
[email protected]
https://www.coherentmarketinsights.com/phase-xs/
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready
syndicated research reports, custom market analysis, consulting services, and competitive analysis
through various recommendations related to emerging market trends, technologies, and potential
absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1–206–701–6702
Email: [email protected]
Author
ravikiran
ravikiran262   documents Email
Document
Category
Health and Medicine
Views
9
File Size
369 KB
Tags
back
1/--pages
Report inappropriate content